HPV-related HNC – new challenge and hope for head and neck cancer subjects
AbstractIn recent years there are observed substantial changes in epidemiology of head and neck cancer. An incidence of laryngeal cancer is declining as a consequence of decreased tobacco smoking. Contrary, oropharyngeal cancer associated with HPV infection transmitted on sexual way is becoming much more frequent. The latter one is characterized with a better prognosis that most likely does not require intensive therapy. De-escalation of therapy in case of HPV-associated tumor is a matter of current studies.
zur Hausen H. Papilloma virus infections – a major cause of human cancers. Bioch Boph Acta. 1996;1288(2):F55–F78.
Sturgis EM, Cinciripini PM. Trends in head and neck cancer incidence in relation to smoking prevalence. Cancer. 2007;110(7):1429–1435.
Pytynia KB, Dahlstrom KR, Sturgis EM. Epidemiology of HPV-associated cancer. Oral Oncol. 2014;50(5):380–386.
Gillison ML, Chaturvedi AK, Anderson WF, Fakhry C. Epidemiology of HPV-positive head and neck squamous cell carcinoma. J Clin Oncol. 2015;33(29):3235–3242.
Chaturvedi AK, Engels EA, Pfeifer RM, Hernandez BY, Xiao W, Kim E et al. HPV and rising oropharyngeal cancer incidence in the United States. J Clin Oncol. 2011;29(32):4294–4301.
Kabeya M, Furuta R, Kawabara K, Takahashi S, Ishikawa Y. Prevalence of HPV in mobile tongue cancer with particular reference to young patients. Cancer Sci. 2012;103(2):161–168.
Rotnaglova E, Tachezy R, Salakova M, Prochazka B, Košlabova E, Vesela E et al. HPV involvement in tonsillar cancer: prognostic significance and clinically relevant markers. Int J Cancer. 2011;129(1):101–110.
Termine N, Panzarella V, Falaschini S, Russo A, Matranga D, Lo Muzio L, Campisi G. HPV in oral squamous cell carcinoma vs head and neck squamous cell carcinoma biopsies: a meta-analysis (1998–2007). Ann Oncol. 2008;19(10):1681–1690.
Qureishi A, Mawby T, Fraser L, Shah KA, Moller H, Winter S. Current and future techniques for HPV testing in oropharyngeal squamous cell carcinoma. Eur J Otorhinolaryngol. 2017;274(12):2675:2683.
Hoffmann M, Tribius S, Quabius ES, Henry H, Pfannenschmidt S, Burkhardt C, et al. HPV DNA E6*I-mRNA expression and p16INK4A immunohistochemistry in head and neck cancer – How valid is p16INK4A as surrogate marker? Cancer Lett. 2012;323(1):88–96.
El-Naggar AK, Westra WH. P16 expression as a surrogate marker for HPV-related oropharyngeal carcinoma: A guide for interpretative relevance and consistency. Head Neck. 2012;34(4):459–461.
Mehanna H, Beech T, Nicholson T, El-Hariry I, McConkey C, et al. Prevalence of HPV in oropharyngeal an nonoropharyngeal head and neck cancer – systematic review and meta-analysis of trends by time and region. Head Neck. 2012;35(2):747–755.
Upile T, Jerjes W, Al-Khawalde M, Rahdi H, Sudhoff H. Oral sex cancer and heath: sexually transmitted cancers. Head Neck Oncol. 2012;4:e31.
Toporcov TN, Znaor A, Zhang ZF, Yu GP, Winn DM, Wei Q, et al. Risk factors and head and neck cancer in young adults: a pooled analysis in the INHANCE consortium. Int J Epidemiol. 2015;44(1):169–185.
Deschler DG, Richmon JD, Khariwala SS, Ferrin RL, Wang MB. The “new” head and neck cancer patients – young, nonsmoker, nondrinker and HPV positive: Evaluation. Otolaryngol Head Neck Surg. 2014;15(3):375–380.
Doorbar J. The papillomavirus life cycle. J Clin Virol. 2005;32(Suppl. 1):S7–S15.
Morshed K, Polz-Gruszka D, Szymański M, Polz-Dacewicz M. Human Papillomavirus (HPV) – structure, epidemiology and pathogenesis. Otolaryngol Pol. 2014;68(5):213–219.
Rampias T, Sasaki C, Psyrri A. Molecular mechanisms of HPV induced carcinogenesis in head and neck. Oral Oncol. 2014;50(5):356–363.
Ha PK, Califano JA. The role of human papillomaviruse in oral carcinogenesis. Crit Rev Oral Biol Med. 2004;15(4):188–196.
Smeets SJ, Braakhuis BJM, Abbas S, Snijders PJF, Ylstra B, van de Wiel MA et al. Genome-wide DNA copy number alterations in head and neck squamous cell carcinomas with or without oncogene-expressing HPV. Oncogene. 2006;25(17):2588–2564.
Olthof NC, Huebbers CU, Koilligs J, Henfling M, Ramaekers FCS, Cornet I, et al. Viral load, gene expression and mapping of viral integration sites in HPV16-associated HNSCC cell lines. Int J Cancer. 2015;136(5):E207–E218.
Korzeniewski N, Spardy N, Duensing A, Duensing S. Genomic instability and cancer: Lessons learned from HPV. Cancer Lett. 2011;305(2):113–122.
Mirghani H, Lacroix L, Rossoni C, Sun R, Auperin A, Casiraghi O, et al. Does smoking alter the mutation profile of human papillomavirus-driven head and cancers? Eur J Cancer. 2018;94:61–69.
Farsi NJ, Russeau MC, Schlecht N, Castoguay G, Allison P, Nguyen-Tan PF, et al. Aetiological heterogeneity of head and neck squamous cell carcinoma: the role of HPV infections, smoking and alcohol. Carcinogenesis. 2017;38(12):1188–95.
Maxwell JH, Kumar B, Feng FY, Worden FP, Lee JS, Eisbruch A, et al. Tobacco use in HPV-positive advanced oropharynx cancer patients releated to increased risk of distant metastases and tumor recurrence. Clin Cancer Res. 2010;16(4):1226–1235.
Young D, Xiao CC, Murphy B, Moore M, Fakhry C, Day TA. Increase in head and neck cancer in younger patients due to HPV. Oral Oncol. 2015;51(8):727–30.
Kaminagakura E, Villa LL, Andreoli MA, Sobrinho JS, Vartanian JG, Soares FA, et al. High-risk HPV in oral squamous cell carcinoma of young patients. Int J Cancer. 2012;130(8):1726–32.
Albers AE, Qian X, Kauffmann A, Coordes A. Meta analysis: HPV and p16 pattern determines survival in patients with HNSCC and identifies potential new biologic subtype. Sci Rep. 2017;7(1):e16715.
Fischer CA, Kampmann M, Zlobec I, Green E, Tornillo L, Lugli A, et al. p16 expression in oropharyngeal cancer: Its impact on staging and prognosis compared with the conventional staging parameters. Ann Oncol. 2010;21(1):961–66.
Nagel R, Martens-de Kemp SR, Buijze M, Jacobs G, Braakhuis BJM, Brakenhoff RH. Treatment response of HPV-positive and HPV-negative head and neck squamous cell carcinoma cell lines. Oral Oncol. 2013;49(6):560–66.
Tribius S, Ihloff AS, Rieckmann T, Petersen C, Hoffmann M. Impact of HPV status on treatment of squamous cell cancer of the oropharynx: What we know and what we need to know. Cancer Lett. 2011;304(2):71–79.
Wierzbicka M, Józefiak A, Szydłowski J, Marszałek A, Stankiewicz Cz, Hassman-Poznańska E, et al. Recommendations for the diagnosis of human papilloma virus (HPV) high and low risk in the prevention and treatment of diseases of the oral cavity, pharynx and larynx. Guide of experts PTORL and KIDL. Otolaryngol Pol. 2013;67(3):113–134.
Laskar SG, Swain M. HPV positive oropharyngeal cancer and treatment deintensification: How pertinent is it? J Cancer Res Therapeutics. 2015;11(1):6–9.
Cheraghlou S, Yu PK, Otremba MD, Park HS, Bhatia Am Zogg CK, et al. Treatment deintensification in HPV-positive otopharynx cancer: Outcomes from the National Cancer Data Base. Cancer. 2018;124(4):717–726.
Stock GT, Bonadio RRCC, de Castro G. De-escalation treatment of HPV-positive oropharyngeal squamous cell carcinoma: an evidence-based review for the locally advanced disease. Curr Opin Oncol. 2018;Epub Feb 22.